SLC9A3
Sodium/hydrogen exchanger 3
As of the edition of 20 October 2026, SLC9A3 (sodium/hydrogen exchanger 3, UniProt P48764) has 3 drugs tested at it and 4 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48764
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Nutrition and metabolism; Eye; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels; Lungs and airways; Nervous system; Cancer
- Registered trials of its drugs
- 48
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tenapanor | Marketed | Phase 4 | Ends 2033 |
| Squalamine | Went quiet | Phase 3 | none listed |
| AVE0657 | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Ardelyx | Route B |
| Ohr Pharmaceutical | Route A |
| Sanofi | Route A |
The other 1 company at SLC9A3
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at SLC9A3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.